Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
171.5 USD | +1.50% | +0.66% | +10.68% |
28/06 | Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU | MT |
28/06 | AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.68% | 30TCr | |
+55.32% | 82TCr | |
+44.05% | 64TCr | |
-6.75% | 35TCr | |
+13.56% | 31TCr | |
+16.57% | 24TCr | |
+13.31% | 22TCr | |
+8.48% | 17TCr | |
-2.81% | 16TCr | |
+0.20% | 12TCr |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie Buys Celsius Therapeutics for $250 million